The newest treatment options for severe uncontrolled asthma include the mAbs anti-IL-4/IL-13 dupilumab [11] and the anti-thymic stromal lymphopoietin (TSLP) tezepelumab [12]. This evidence concerns the gene IL4 and asthma.